Holen Sie sich die Stockscreener-App
68.44
0.44%
0.295
Schlusskurs vom Vortag:
$68.14
Offen:
$67.87
24-Stunden-Volumen:
898.36K
Relative Volume:
0.35
Marktkapitalisierung:
$13.11B
Einnahmen:
$353.78M
Nettoeinkommen (Verlust:
$-805.69M
KGV:
-16.35
EPS:
-4.1869
Netto-Cashflow:
$-597.61M
1W Leistung:
-9.05%
1M Leistung:
-12.11%
6M Leistung:
+39.45%
1J Leistung:
+85.73%
1-Tages-Spanne:
$67.51
$69.50
1-Wochen-Bereich:
$67.42
$76.81
52-Wochen-Spanne:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
68.44 | 13.06B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.10 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.52 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.83 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.85 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Insights Ahead: BridgeBio Pharma's Quarterly Earnings - Benzinga
BridgeBio to Participate in March Investor Conferences - The Manila Times
Biotech BridgeBio plans three March investor conference chats - Stock Titan
Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?BridgeBio Pharma (NASDAQ:BBIO), BorgWarner (NYSE:BWA), Expedia Group (NASDAQ:EXPE), Flutter Entertainment ( - Benzinga
BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC - MarketBeat
BridgeBio Pharma Inc (BBIO) Stock Price, Quote, News & History - Benzinga
BridgeBio Pharma Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BridgeBio (BBIO) Shares Dip After UBS Summit Withdrawal - GuruFocus
16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - Defense World
Bank of America Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO - Defense World
HC Wainwright Boosts Earnings Estimates for BridgeBio Pharma - MarketBeat
NEOS Investment Management LLC Has $5.02 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CFO Sells 13,600 Shares of Stock - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Director Randal Scott Sells 10,000 Shares - MarketBeat
BridgeBio Pharma director Scott sells $754k in BBIO stock - Investing.com
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock By Investing.com - Investing.com Canada
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock - Investing.com
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
BridgeBio earnings up next: Can pipeline wins fuel growth? By Investing.com - Investing.com Canada
BridgeBio earnings up next: Can pipeline wins fuel growth? - Investing.com Australia
BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP - MarketBeat
Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Insider Monkey
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00 - MarketBeat
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
BBIO: Today's Analyst Rating Insights by HC Wainwright & Co. | B - GuruFocus
BBIO stock surges 17% pre-market today – what’s fueling the rally? - MSN
Is BridgeBio Pharma Inc. still a buy after recent gainsJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Published on: 2026-02-15 17:09:25 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail
Is BridgeBio Pharma Inc. a stock for growth or value investorsJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week - Proactive financial news
Is BridgeBio Pharma Inc. a speculative investment2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer - MarketBeat
BBIO: Oppenheimer Raises Price Target for BridgeBio Pharma | BBI - GuruFocus
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo - Morningstar
Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating - marketscreener.com
BBIO: Wells Fargo Raises Price Target to $98 While Maintaining 'Overweight' Rating | BBIO Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com - Investing.com Canada
BBIO Stock Surges 19% With A 5-day Spree On Positive Phase 3 Trial Data - Trefis
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026 - Meyka
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Apuli Maricel | Chief Accounting Officer |
Feb 17 '26 |
Sale |
74.31 |
510 |
37,898 |
123,945 |
| Trimarchi Thomas | President and CFO |
Feb 17 '26 |
Sale |
74.72 |
13,600 |
1,016,147 |
336,585 |
| Scott Randal W. | Director |
Feb 17 '26 |
Option Exercise |
16.75 |
10,000 |
167,500 |
21,589 |
| Scott Randal W. | Director |
Feb 17 '26 |
Sale |
75.46 |
10,000 |
754,557 |
11,589 |
0.81%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):